Safety, Tolerability and Fat Absorption Using Enteral Feeding In-line Enzyme Cartridge (Relizorb)

Completed · Not applicable · Has a placebo group

Conditions studied: Exocrine Pancreatic Insufficiency

In brief

Protocol ALCT-0000497 is a multicenter safety, tolerability and fat absorption study that anticipates enrolling 35 male and female subjects (pediatric and adult) with cystic fibrosis. Subjects with confirmed exocrine pancreatic insufficiency will use a novel enteral feeding in-line digestive enzyme cartridge (RELiZORB) connected to enteral pump sets.

Key facts

Study ID
NCT02598128
Run by
Alcresta Therapeutics, Inc.
People needed
34
Starts
2015-11-01
Expected to finish
2016-06-01
Last updated by the study team
2017-01-25

Who can join

Age: 4 and older, up to 45. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

You may not qualify if…

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.